Sensus Healthcare’s (NASDAQ:SRTS) superficial radiation therapy (SRT) demonstrated a 98.9% skin cancer cure in a five-year retrospective study.
Sensus’ SRT is a low-energy X-ray technology used to treat non-melanoma skin cancer (NMSC) and keloids. The study, in which Sensus’ SRT treated 776 NMSC lesions in 516 patients, yielded topline results demonstrating 1.1% cumulative recurrence rates of all tumors at both two and five years post-treatment.
“Sensus is committed to advancing research and development for optimal SRT treatment to improve patient outcomes, and we look forward to presenting detailed study results at an upcoming scientific meeting,” Isabelle Raymond, Sensus’ VP clinical development, said in a statement.
